Product
pyrotinib+capecitabine+bevacizumab
1 clinical trial
1 indication
Indication
Metastatic Breast CancerClinical trial
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases：a Single-arm,Prospective,Phase II StudyStatus: Recruiting, Estimated PCD: 2024-11-30